Miles Trasylol
Executive Summary
Firm files supplemental NDA for use of the drug at half the currently approved dose. Aprotinin was approved Dec. 29 to prevent blood loss and the need for transfusion in repeat coronary artery bypass graft surgery patients, and in some primary CABG patients at high risk of bleeding or who cannot have transfusions ("The Pink Sheet" Jan. 3, p. 6)